Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Blocking Constant Interferon Signaling Allows the Immune System to Clear Chronic Viral Infections

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Blocking constant Type I interferon (IFN-I) signaling in mice diminished chronic immune activation and immune suppression and enabled the animals' immune system to rejuvenate and ultimately clear persistent viral infections.

Interferons (IFNs) are glycoprotein cytokines made and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, or tumor cells. They allow for communication between cells to trigger the protective defenses of the immune system that eradicate pathogens or tumors. Interferons were named after their ability to "interfere" with viral replication within host cells. IFNs have other functions: they activate immune cells, such as natural killer cells and macrophages; they increase recognition of infection or tumor cells by up-regulating antigen presentation to T-lymphocytes; and they increase the ability of uninfected host cells to resist new viral infection. Certain symptoms, such as aching muscles and fever, are related to the production of IFNs during infection. While Type I interferons (IFN-I) are critical for antiviral immunity, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections.

Investigators at the University of California, Los Angeles (USA) injected mice suffering from chronic viral infections with an antibody that temporarily blocked IFN-I activity.

They reported in the April 12, 2013, issue of the journal Science that the blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T-cells and was associated with enhanced IFN-gamma production.

“When cells confront viruses, they produce Type I interferons, which trigger the immune system’s protective defenses and sets off an alarm to notify surrounding cells,” said senior author Dr. David Brooks, assistant professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. “Type-I interferon is like the guy in the watch tower yelling, "Red alert,” when the marauders try to raid the castle.”

“What we saw was entirely illogical,” said Dr. Brooks. “We had blocked something critical for infection control and expected the immune system to lose the fight against infection. Instead, the temporary break in IFN-I signaling improved the immune system’s ability to control infection. Our next task will be to figure out why and how to harness it for therapies to treat humans.”

Related Links:
University of California, Los Angeles



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.